Laboratory Diagnostics for Thrombosis and Hemostasis Testing—Part I

Kristi J. Smock; Robert C. Gosselin

doi:10.1055/s-0042-1755367

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2022; 48(06): 631-633
DOI: 10.1055/s-0042-1755367

Preface

Laboratory Diagnostics for Thrombosis and Hemostasis Testing—Part I

Authors

Kristi J. Smock

¹Department of Pathology and ARUP Laboratories, University of Utah, Salt Lake City, Utah
Robert C. Gosselin

²Hemostasis and Thrombosis Center, University of California, Davis Health System, Sacramento, California

Abstract

Volltext

Referenzen

References
1 Gosselin RC, Marlar RA. Preanalytical variables in coagulation testing: setting the stage for accurate results. Semin Thromb Hemost 2019; 45 (05) 433-448
2 Chen Q, Shou W, Wu W. et al. Biological and analytical variations of 16 parameters related to coagulation screening tests and the activity of coagulation factors. Semin Thromb Hemost 2015; 41 (03) 336-341
3 Favaloro EJ, Lippi G, Adcock DM. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis?. Semin Thromb Hemost 2008; 34 (07) 612-634
4 Moore GW. Testing for lupus anticoagulants. Semin Thromb Hemost 2022; 48 (06) 643-660
5 Devreese KMJ. Solid phase assays for antiphospholipid antibodies. Semin Thromb Hemost 2022; 48 (06) 661-671
6 Tachil J, Favaloro EJ, Lippi G. D-dimers–“normal” levels versus elevated levels due to a range of conditions, including “D-dimeritis,” inflammation, thromboembolism, disseminated intravascular coagulation, and COVID-19. Semin Thromb Hemost 2022; 48 (06) 672-679
7 Morimont L, Donis D, Bouvy C, Mullier F, Dogne JM, Douxfils J. Laboratory testing for the evaluation of phenotypic activated protein C resistance. Semin Thromb Hemost 2022; 48 (06) 680-689
8 Salazar E, Long TA, Smock K. et al. Analysis of College of American Pathologists von Willebrand Factor Proficiency Testing Program. Semin Thromb Hemost 2022; 48 (06) 690-699
9 Ziemba YC, Abdulrehman J, Hollestelle MJ, Meijer P, Plumhoff E. Hsu Peihong, Selby R. Diagnostic testing for von Willebrand disease: trends and insights from North American laboratories over the last decade. Semin Thromb Hemost 2022; 48 (06) 700-710
10 Favaloro EJ, Dean E, Arunachalam S. Evaluating performance of contemporary and historical von Willebrand factor (VWF) assays in the laboratory identification of von Willebrand disease (VWD): the Australasian experience. Semin Thromb Hemost 2022; 48 (06) 711-731
11 Jennings I, Reilly-Stitt C, Lowe A, Kitchen S, Walker I. External quality assessment data for investigation of von Willebrand disease: focus on relative utility of contemporary functional von Willebrand factor assays. The United Kingdom National External Quality Assessment Scheme (UK NEQAS) experience. Semin Thromb Hemost 2022; 48 (06) 732-738
12 Hollestelle MJ, Meijers JCM, Meijer P. How do laboratories perform von Willebrand disease (VWD) diagnostics and classification of VWD patients? Results from external quality data and an international survey. Semin Thromb Hemost 2022; 48 (06) 739-749
13 Favaloro EJ, Pasalic L. Laboratory diagnosis of von Willebrand disease (VWD): geographical perspectives. Semin Thromb Hemost 2022; 48 (06) 750-766
14 James PD, Connell NT, Ameer B. et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv 2021; 5 (01) 280-300
15 Kalot MA, Husainat N, El Alayli A. et al. von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. Blood Adv 2022; 6 (01) 62-71
16 Nichols WL, Rick ME, Ortel TL. et al. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol 2009; 84 (06) 366-370
17 Laffan MA, Lester W, O'Donnell JS. et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (04) 453-465
18 Sadler JE, Budde U, Eikenboom JCJ. et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
19 Favaloro EJ, Mohammed S, Vong R. et al. How we diagnose 2M von Willebrand disease (VWD): use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types. Haemophilia 2021; 27 (01) 137-148
20 Favaloro EJ. Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol 2021; 43 (04) 559-570
21 Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J. von Willebrand factor Subcommittee of the Standardization and Scientific Committee of the International Society for Thrombosis and Haemostasis. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (07) 1345-1350